Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus.

@article{Llorente2000ClinicalAB,
  title={Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus.},
  author={Luis Llorente and Yvonne Richaud-Pat{\'i}n and Carlos Garc{\'i}a-Padilla and Emmanuel Claret and Juan J{\'a}kez-Ocampo and Mario H Cardiel and Jorge Alcocer-Varela and Liliane Grangeot-Keros and Donato Alarc{\'o}n-Segovia and John Wijdenes and Pierre Galanaud and Dominique Emilie},
  journal={Arthritis and rheumatism},
  year={2000},
  volume={43 8},
  pages={1790-800}
}
OBJECTIVE To evaluate the safety and clinical efficacy of administering an anti-interleukin-10 (anti-IL-10) monoclonal antibody (mAb) to systemic lupus erythematosus (SLE) patients with active and steroid-dependent disease. In addition, we sought to assess the effects of in vivo IL-10 neutralization on biologic markers of SLE. METHODS Treatment consisted of 20 mg/day intravenous administration of an anti-IL-10 murine mAb (B-N10) for 21 consecutive days, with a followup period of 6 months. Six… CONTINUE READING